1. C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia
- Author
-
Soo-Kyung Shim, Je-Hwan Lee, Jung-Hee Lee, Hee-Jung Lee, Kyoo-Hyung Lee, M. Kang, Seong-Gil Ryu, Young-Shin Lee, Chan-Jeoung Park, Yae Eun Jang, Michael Jinpyo Lee, Miee Seol, Hyun-Sook Chi, Eun-Hye Hur, Ip-Sol Kang, Seong-Jun Choi, and Young-Ah Kang
- Subjects
Adult ,Male ,Cancer Research ,ATP Binding Cassette Transporter, Subfamily B ,Genotype ,Polymorphism, Single Nucleotide ,Medicine ,Humans ,In patient ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,neoplasms ,P-glycoprotein ,C3435t polymorphism ,biology ,business.industry ,Myeloid leukemia ,Hematology ,Mdr1 gene ,Survival Analysis ,Genotype frequency ,Leukemia, Myeloid, Acute ,Treatment Outcome ,Oncology ,Immunology ,biology.protein ,Female ,Genes, MDR ,business ,Leukemic Blasts - Abstract
We investigated the association between the MDR1 C3435T polymorphism and P-glycoprotein function of leukemic blasts as well as clinical outcomes in 200 patients with AML, excluding the M3 subtype. The CC, CT and TT genotype frequencies of the C3435T polymorphism among patients were 71, 93 and 36, respectively. The C3435T polymorphism genotypes did not have influence on the P-glycoprotein function of leukemic blasts. Complete remission rates and overall, relapse-free and event-free survival rates were not significantly different among the C3435T polymorphism genotypes. In conclusion, the MDR1 C3435T polymorphism does not appear to have significant clinical implications in AML.
- Published
- 2007